CFO Greg Cavers Buys $38,730 of Helus Pharma Stock at $12.91
HELP has more than doubled off its 52-week low of $3.76.
Summary
Helus Pharma CFO Greg Cavers bought $38,730 of company stock on the open market at $12.91 per share, continuing a 90-day insider accumulation trend with no insider selling.
Key Events · Ownership and Investor Activity · HELP
-
CFO Open-Market Purchase
CFO Greg Cavers bought 3,000 shares at $12.91 per share on 2026-09-29, totaling $38,730. Shares are held indirectly by his spouse.
-
Insider Accumulation Trend
This purchase extends a 90-day pattern: three insiders have bought approximately $9.6 million of stock with zero open-market sales, signaling broad internal confidence.
-
Financial Context
The buy comes after Helus Pharma reported a $47.8 million quarterly net loss with $166.4 million in cash, and while Phase 3 APPROACH data for HLP003 remains pending.
-
Post-Transaction Holdings
Cavers now holds 125,937 shares directly plus 3,000 shares indirectly through his spouse.
Analysis · HELP · Life Sciences
CFO Greg Cavers bought 3,000 shares on the open market at $12.91 per share, spending $38,730. The purchase is held indirectly by his spouse. This adds to a broader pattern of insider accumulation at Helus Pharma — three insiders have bought roughly $9.6 million of stock over the past 90 days, with no open-market sales. A CFO putting personal capital to work is a meaningful vote of confidence, especially at a company that recently reported a $47.8 million quarterly loss and is awaiting Phase 3 data for its lead depression drug.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1504 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HELP was trading at $11.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $3.76 to $15.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.